Tapering Strategies

This article reviews a retrospective study evaluating the feasibility and outcomes of a 24-week abrocitinib tapering regimen in moderate-to-severe atopic dermatitis, comparing dose reduction versus interval extension approaches and their impact on efficacy, safety, and cost.